更新的治疗方法,以eosinophilic granulomatosis与多炎:一个系统的范围审查审查
Mayu Shiomi1, Tomoaki Higuchi2, Mitsuhiro Akiyama3
1Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Japan.
Modern rheumatology
|December 22, 2025
概括
与标准护理相比,利图西马布在聚炎 (EGPA) 带来的埃索诺菲尔粒状瘤症中没有明显的益处. 本拉利祖马布在EGPA治疗中表现出与梅波利祖马布相似的疗效和安全性,尽管需要更多的研究.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 临床试验 临床试验
背景情况:
- 带有多炎 (EGPA) 的异性粒状炎是一种罕见的,严重的自身免疫性血管炎.
- 新的生物疗法,包括IL-5抑制剂,正在为EGPA管理而出现.
- 临床实践指南需要根据新证据定期更新.
研究的目的:
- 在EGPA中评估rituximab的疗效和安全性.
- 评估本拉利祖马布在EGPA中的疗效和安全性.
- 为EGPA治疗提供最新的证据基础.
主要方法:
- 进行了范围审查,以确定临床问题.
- 进行了2018年12月 - 2023年7月发表的随机对照试验 (RCT) 的系统审查.
- 评估偏差风险 (RoB2) 和证据质量 (GRADE).
主要成果:
- 一个RCT (n=105) 发现Rituximab在缓解率与常规疗法 (63.5%与60.4%) 之间没有显著差异,确定性非常低.
- 另一项RCT表明,本拉利祖马布的缓解和复发率与梅波利祖马布相似,确定性较低.
- 对于这两种药物,关于长期结果和安全性概况的数据有限.
结论:
- 利图西马布似乎没有在EGPA常规治疗中提供明显的优势.
- 本拉利祖马布在EGPA中显示出与梅波利祖马布相比的有效性和安全性.
- 进一步高质量的EGPA特定试验对于证实这些发现和指导治疗决策至关重要.
相关概念视频
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
418
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
418
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
435
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
435
01:26Peptic Ulcer Disease IV: Management
397
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
397
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
413
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
413
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
274
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
274